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Abstract
The emergence of community-associated methicillin-resistant Staphylococcus aureus
(MRSA), including strains resistant to current antibiotics, has contributed to an increase in
the number of skin infections reported in humans in recent years. New therapeutic options
are needed to counter this public health challenge. The aim of the present study was to
examine the potential of thiazole compounds synthesized by our research group to be used
topically to treat MRSA skin and wound infections. The broth microdilution method con-
firmed that the lead thiazole compound and four analogues are capable of inhibiting MRSA
growth at concentrations as low as 1.3 μg/mL. Additionally, three compounds exhibited a
synergistic relationship when combined with the topical antibiotic mupirocin against MRSA
in vitro via the checkerboard assay. Thus the thiazole compounds have potential to be used
alone or in combination with mupirocin against MRSA. When tested against human kerati-
nocytes, four derivatives of the lead compound demonstrated an improved toxicity profile
(were found to be non-toxic up to a concentration of 20 μg/mL). Utilizing a murine skin infec-
tion model, we confirmed that the lead compound and three analogues exhibited potent
antimicrobial activity in vivo, with similar capability as the antibiotic mupirocin, as they
reduced the burden of MRSA present in skin wounds by more than 90%. Taken altogether,
the present study provides important evidence that these thiazole compounds warrant fur-
ther investigation for development as novel topical antimicrobials to treat MRSA skin
infections.
Introduction
Ten percent of all hospital admissions in the United States each year are due to patients suffer-
ing from skin and soft tissue infections (SSTIs) [1]. SSTIs can range from simple abscesses,
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cellulitis, and traumatic wound infections to complicated infections (infected burns, diabetic
foot ulcers, and major abscesses) [1]. SSTIs are often caused by the bacterial pathogen methicil-
lin-resistant Staphylococcus aureus (MRSA) [2, 3]. Indeed, 58% of all SSTIs treated in the
United States alone were caused by MRSA, according to an epidemiological study of one
national health care system [4]. This agrees with a 2004 study conducted in emergency room
departments in 11 cities where MRSA was responsible for 59% of patients presenting with a
SSTI [5]. The large number of S. aureus-based SSTIs has placed a significant economic burden
on the healthcare system. A recent report examining the increase in S. aureus-SSTI hospitaliza-
tions in the United States documented a dramatic rise in the annual cost of treating infected
patients from $3.36 billion to $4.50 billion (from the years 2001 through 2009) [6]. A recent
increase in skin abscesses has been observed and has been associated with a rise in strains of
community-associated MRSA (CA-MRSA) [7]. Of these strains, MRSA USA300 has been
linked most frequently to skin infections in the United States [5, 8].
According to guidelines provided by the Infectious Diseases Society of America, treatment
of moderate to severe skin infections caused by MRSA involves incision and drainage of the
affected region combined with administration of empirical antibiotics (such as clindamycin,
vancomycin, linezolid, and mupirocin) [9, 10]. However, strains of MRSA exhibiting resistance
to several of these antibiotics including vancomycin [11, 12], clindamycin [13, 14], and topical
ointments like mupirocin [14–16], indicate that such therapies may be rendered ineffective in
the future. Therefore, development of novel antimicrobials capable of treating MRSA-induced
SSTIs is an important step necessary to circumvent the burden of this public health issue.
Previous research by our group has identified a lead disubstituted phenylthiazole compound
(compound 1, Fig 1) that exhibited potent antimicrobial activity in vitro against a diverse array
of clinically-significant strains of MRSA [17]. Derivatives of the lead 1 were synthesized to elu-
cidate the structure-activity relationships of this compound. These derivatives revealed that the
aminoguanidine moiety at thiazole-C5 is critical for antibacterial activity [18]. Furthermore, a
nonpolar, hydrophobic group is favored at thiazole-C2. Analogues to the lipophilic alkyl tail of
the lead 1 were subsequently constructed in order to enhance the antimicrobial activity of these
thiazole compounds, to improve their toxicity profile, and to refine their physicochemical
properties [18]. These particular phenylthiazole compounds possess several excellent charac-
teristics in vitro including rapid bactericidal activity against MRSA, a low frequency of bacterial
resistance developing, and they have been shown to possess the ability to be used in combina-
tion with currently approved antibiotics, such as vancomycin, against MRSA [19]. Studies per-
formed to date indicate these compounds have potential to be used as topical antimicrobials
for treatment of MRSA skin infections. The objectives of the current study were to assess the
antibacterial activity of the lead thiazole compound and four analogues (Fig 1) in vitro against
antibiotic-resistant S. aureus strains isolated from/responsible for skin infections, to assess the
ability of these compounds to be paired with mupirocin as a treatment option against MRSA,
to confirm the compounds have limited toxicity to human keratinocytes, and to verify the thia-
zole compounds can retain their antimicrobial activity in vivo in an established murine MRSA
skin infection model. Confirmation of the ability of these compounds to successfully treat mice
infected with a MRSA skin infection will lay the foundation for further assessment of these
compounds as novel antimicrobials for treatment of MRSA skin infections.
Materials and Methods
Synthesis of thiazole compounds 1–5
Synthetic schemes, spectral data, and purity (>95%, determined by HPLC) of thiazole com-
pounds 1–5 (Fig 1), in addition to all intermediates, have been reported elsewhere [17, 18, 20].
Thiazole Compounds Treat MRSA Skin Infections
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Bacterial strains and reagents used in this study
Clinical isolates of S. aureus were obtained through the Network of Antimicrobial Resistance
in Staphylococcus aureus (NARSA) program (Table 1). Clindamycin hydrochloride monohy-
drate (TCI America, Portland, OR, USA,>98.0% purity) and mupirocin (pure USP) (Appli-
Chem, St. Louis, MO, USA) powders were purchased commercially and dissolved in dimethyl
sulfoxide (DMSO) (for clindamycin) or ethanol (for mupirocin) to prepare a stock solution
(10 μg/mL). Lipoderm was purchased from the Professional Compounding Centers of America
(Houston, TX, USA). Cation-adjusted Mueller-Hinton broth (CAMHB) (Sigma-Aldrich,
St. Louis, MO, USA), Tryptic soy broth (TSB) (Becton, Dickinson and Company, Franklin
Lakes, NJ, USA), mannitol salt agar (Hardy Diagnostics, Santa Maria, CA, USA), phosphate-
buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO, USA), Dulbeco’s modified Eagle’s
medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA), fetal bovine serum (FBS) (USA Scien-
tific, Inc., Orlando, FL, USA), petroleum jelly (Equate [Walmart, Inc.], Bentonville, AR, USA),
and 96-well plates (CellTreat Scientific Products, Shirley, MA, USA) were all purchased from
commercial vendors.
Determination of minimum inhibitory concentration (MIC) against drug-
resistant S. aureus strains
The MIC of thiazole compounds 1–5, clindamycin, and mupirocin was determined against five
different MRSA strains and one highly mupirocin-resistant S. aureus strain isolated from skin
wounds, using the broth microdilution method, following the guidelines outlined by the Clini-
cal and Laboratory Standards Institute [21]. A bacterial suspension equivalent to a McFarland
Fig 1. Chemical structures of thiazole compounds 1–5 presented in this study.
doi:10.1371/journal.pone.0142321.g001
Table 1. Drug-resistant clinical isolates of Staphylococcus aureus used in this study.
NARSA1 Strain ID Alternate Strain Designation US State Isolated From Year Isolated Antimicrobial Resistance Phenotype
NRS107 RN4220 Connecticut 1991 Highly mupirocin-resistant and rifampicin
NRS123(MRSA) USA400 North Dakota 1998 β-lactams
NRS384(MRSA) USA300-0114 Mississippi - Erythromycin, β-lactams, and tetracycline
NRS387(MRSA) USA800 Washington - β-lactams and fluoroquinolones
NRS483(MRSA) USA1000 Vermont 1993–1994 Erythromycin and methicillin
NRS484(MRSA) USA1100 Alaska 1996 β-lactams
1NARSA, Network on Antimicrobial Resistance in Staphylococcus aureus.
doi:10.1371/journal.pone.0142321.t001
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standard of 0.5 was prepared and subsequently diluted 1:300 in CAMHB. This bacterial sus-
pension (~1 × 105 colony forming unit (CFU/mL)) was then added to each well of a 96-well
microtiter plate. Compounds 1–5, clindamycin, or mupirocin were added (in triplicate) to the
first row of the plate and then serially diluted down the ordinate. Plates were incubated at 37°C
for 18–20 hours and then the MIC was ascertained. The MIC was classified as the lowest con-
centration of each test agent where bacterial growth could not be visualized.
Assessment of synergistic relationship between thiazole compounds
and mupirocin against MRSA
The checkerboard assay was utilized to asses if the most potent thiazole compounds (1–3) have
potential to be combined with mupirocin for treatment of MRSA infections [22]. Briefly, a bac-
terial suspension (1 × 105 CFU/mL) in CAMHB was added to each well of a 96-well microtiter
plate. Compounds 1–3 and mupirocin were diluted in CAMHB in order to reach the desired
starting concentration (2 × or 4 × MIC). Mupirocin was serially diluted along the horizontal
axis of the plate while compound 1, 2, or 3 was diluted along the vertical axis. Plates were incu-
bated for at least 18 hours at 37°C and the MIC of each compound was recorded. The fractional
inhibitory concentration index (ƩFIC) was computed for each combination using the following
equation:
X
FIC ¼ MICthiazole compound in combination with mupirocin
MICthiazole compound alone
 
þ MICmupirocin in combination with thiazole compound
MICmupirocin alone
 
A FIC index less than or equal to 0.50 was classified as synergism, as described previously
[19]. FIC values above 0.50 but less than 4.00 were classified as indifference, while FIC values
greater than 4.00 were indicative of antagonism.
In vitro cytotoxicity analysis of thiazole compounds against HaCaT cells
Compounds 1–5 were assayed (at concentrations of 5 μg/mL, 10 μg/mL, 20 μg/mL, and
40 μg/mL) against a human keratinocyte (HaCaT) cell line (Catalogue Number: T0020001,
AddexBio, San Diego, CA, USA) to determine the potential toxic effect to mammalian skin
cells in vitro as described before [18]. Briefly, cells were cultured in DMEM supplemented with
10% FBS at 37°C with CO2 (5%). Control cells received DMSO alone at a concentration equal
to that in drug-treated cell samples. The cells were incubated with the compounds (in tripli-
cate) in a 96-well plate at 37°C with CO2 (5%) for two hours prior to addition of the assay
reagent MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) (Promega, Madison, WI, USA). Absorbance readings (at OD490) were taken
using a kinetic microplate reader (Molecular Devices, Sunnyvale, CA, USA). The quantity of
viable cells after treatment with each compound was expressed as a percentage of the viability
of DMSO-treated control cells (average of triplicate wells ± standard deviation). The toxicity
data was analyzed via a one-way ANOVA, with post hoc Dunnet’s multiple comparisons test
(P< 0.05), utilizing GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA).
In vivo assessment of antimicrobial activity of thiazole compounds 1–5
and mupirocin in a MRSA skin infection mouse model
The MRSA murine skin infection study was reviewed, approved, and performed under the
guidelines of the Purdue University Animal Care and Use Committee (PACUC) (protocol
Thiazole Compounds Treat MRSA Skin Infections
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number: 1207000676) and carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. To ini-
tiate the formation of a skin wound, eight groups (n = 5) of eight-week old female Balb/c mice
(obtained from Harlan Laboratories, Indianapolis, IN, USA) were disinfected with ethanol
(70%) and shaved on the middle of the back (approximately a one-inch by one-inch square
region around the injection site) one day prior to infection, similar to what has been described
elsewhere [23, 24]. To prepare the bacterial inoculum, an aliquot of overnight culture of MRSA
USA300 was transferred to fresh TSB and shaken at 37°C until an OD600 value of ~1.0 was
achieved. The cells were centrifuged, washed once with PBS, re-centrifuged, and then re-sus-
pended in PBS. Mice then received an intradermal injection (20 μL) containing ~2.76 × 108
CFU/mL MRSA USA300. An open wound formed at the site of injection, 48 hours post-infec-
tion. Topical treatment was initiated subsequently with each group of mice receiving the fol-
lowing: compound 1–5 (2%, using petroleum jelly as the vehicle), mupirocin (2%, using
petroleum jelly as the vehicle), compound 1 (2%, using Lipoderm as an alternative vehicle),
and a control group receiving the control vehicle (20 mg, petroleum jelly) alone. Each group of
mice receiving a particular treatment regimen was housed separately in a ventilated cage with
appropriate bedding, food, and water. Mice were checked twice daily during infection and
treatment to ensure no adverse reactions were observed. In the event a mouse was observed to
become severely ill, the subject was euthanized per the IRB protocol. Mice were treated twice
daily for three days. Mice were humanely euthanized via CO2 asphyxiation 24 hours after the
last dose was administered. The region around the skin wound was lightly swabbed with etha-
nol (70%) and excised. The tissue was subsequently homogenized in TSB (1 mL). The homoge-
nized tissue was then serially diluted in PBS before plating onto mannitol salt agar plates. The
plates were incubated for 20–22 hours at 37°C before viable CFU were counted and MRSA
reduction in the skin wound post-treatment was determined for each group. Data were ana-
lyzed using a one-way ANOVA, with post hoc Holm-Sidak’s multiple comparisons test
(P< 0.05), utilizing GraphPad Prism 6.0.
Results and Discussion
Antimicrobial activity of thiazole compounds 1–5 against MRSA strains
isolated from skin wounds
Previous work has established thiazole compounds 1–5 possess potent antimicrobial activity
against MRSA (particularly isolates derived from healthcare-associated MRSA cases). To con-
firm these compounds maintain their antibacterial activity against CA-MRSA strains and
MRSA isolates derived from patients presenting with infected wounds (Table 1), the broth
microdilution assay was utilized to determine the lowest concentration each compound was
able to inhibit the growth of these strains (denoted as the minimum inhibitory concentration
or MIC).
When tested against these important clinical isolates of drug-resistant S. aureus, the thiazole
compounds exhibited strong antimicrobial activity similar to (and in several cases better than)
mupirocin. As presented in Table 2, the lead thiazole 1 exhibits the most potent activity with a
MIC value of 1.3 μg/mL against all six drug-resistant staphylococcal strains tested. The biphe-
nyl and butyne analogues (2 and 3, respectively) possess MIC values ranging from 2.8 to
5.6 μg/mL. All five thiazole compounds possess antimicrobial activity against MRSA strains
exhibiting resistance to an array of antibiotics including β-lactams, fluoroquinolones
(USA800), tetracycline (USA300), and erythromycin (USA300 and USA1000). This indicates
cross-resistance between these antibiotics and the thiazole compounds is unlikely to occur.
Additionally, the compounds exhibit potent antimicrobial activity against S. aureus NRS107
Thiazole Compounds Treat MRSA Skin Infections
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(MIC values range from 1.3 to 13.3 μg/mL), a strain exhibiting a high-level of resistance to
mupirocin (MIC of 1024.0 μg/mL). Furthermore, compounds 1 and 2 (MIC of 1.3 and 2.8 μg/
mL, respectively) are more active than mupirocin (MIC of 4.0 μg/mL) against three additional
MRSA strains (USA800, USA1000, and USA1100). Clindamycin, when tested against four of
the five MRSA strains, was found to have a MIC of 0.1 μg/mL. This MIC value is similar to
what has been reported elsewhere for clindamycin [25]. Collectively, the results confirm that
the thiazole compounds do possess potent antimicrobial activity against important CA-MRSA
strains and MRSA isolates responsible for infected wounds in patients.
Combination therapy using thiazole compounds with mupirocin against
MRSA
The susceptibility analysis performed with the thiazole compounds indicated they have poten-
tial to be used alone for the treatment of MRSA skin/wound infections. While the use of a sin-
gle agent to treat such infections is often used in the clinical setting, combination therapy using
two or more antibiotics is favorable for multiple reasons. Among these reasons include that
combination therapy has the potential to slow down the emergence of resistant bacterial strains
to antibiotics, to reduce potential negative side effects to patients (by using lower concentra-
tions/doses of each drug), and to alleviate the morbidity related to bacterial infections [26, 27].
Given that multiple topical treatments for skin infections involve a combination of more than
one antibiotic, such as Neosporin (consisting of bacitracin, neomycin, and polymyxin B sul-
fate) and Polysporin ointment (consisting of bacitracin, polymyxin B sulfate, and gramicidin)
[28], the identification of compounds to pair with known antibiotics has good potential to
expand the available treatment options. Mupirocin has been a key ally in the treatment of
MRSA skin infections; however, isolates exhibiting moderate to high-level of resistance to
mupirocin (MIC 512 μg/mL) have emerged, particularly in environments where this antibi-
otic has been extensively utilized [15, 29, 30]. Identifying agents that can be partnered with
mupirocin has the potential to extend the usage of this particular antimicrobial in the clinical
setting.
In an earlier study, Alou et al, demonstrated that mupirocin forms a synergistic relationship
with amoxicillin-clavulanate against MRSA isolates tested in vitro via the checkerboard assay
[31]. Amoxicllin is a β-lactam antibiotic that interferes with bacterial cell wall synthesis by
inhibiting crosslinking of peptidoglycan subunits in the bacterial cell wall [32]. Preliminary
studies conducted with our thiazole compounds indicate they also interfere with cell wall syn-
thesis in bacteria; thus we were curious to assess if the thiazole compounds could be used in
combination with mupirocin against MRSA, similar to what was found with amoxicillin-
Table 2. Minimum inhibitory concentration (MIC in μg/mL) of thiazole compounds 1–5, clindamycin, andmupirocin (tested in triplicate) against
five methicillin-resistant Staphylococcus aureus (MRSA) and onemupirocin-resistant S. aureus (NRS107) strain isolated from skin wounds.
S. aureus Strain Number
Compound Number/Name NRS107 USA300 USA400 USA800 USA1000 USA1100
1 1.3 1.3 1.3 1.3 1.3 1.3
2 2.8 2.8 2.8 2.8 2.8 2.8
3 2.8 5.6 5.6 5.6 2.8 5.6
4 13.3 13.3 13.3 13.3 13.3 13.3
5 6.4 6.4 12.8 6.4 12.8 6.4
Clindamycin 0.1 1.8 0.1 0.1 0.1 0.1
Mupirocin 1024.0 1.0 1.0 4.0 4.0 4.0
doi:10.1371/journal.pone.0142321.t002
Thiazole Compounds Treat MRSA Skin Infections
PLOS ONE | DOI:10.1371/journal.pone.0142321 November 4, 2015 6 / 13
clavulanate. Using the checkerboard assay, it was discovered that the most potent thiazole com-
pounds (1–3) exhibited a strong degree of synergy (FIC index 0.50) with mupirocin against
two of the most prevalent MRSA strains responsible for skin infections (Table 3). Against
MRSA USA300, all three compounds exhibited a fractional inhibitory concentration (FIC)
index ranging from 0.09 to 0.13 when combined with mupirocin. A similar trend was observed
when this combination was tested against MRSA USA400, with FIC values ranging from 0.05
to 0.13. The data provide evidence that supports the prospect that these particular thiazole
compounds can be successfully paired with mupirocin to treat MRSA infections (and poten-
tially prolong the utility of mupirocin in the clinical setting).
Toxicity analysis of thiazole compounds to human keratinocytes
Selective toxicity is important to ensure compounds with promising antimicrobial activity
don’t possess negative side effects to mammalian tissues. Certain regimens (in particular anti-
septics) used for treatment of skin infections and wounds have been found to exhibit toxicity to
human keratinocytes and impair wound healing, thus limiting their use as therapeutic options
[33–36]. Prior to validating the antimicrobial activity of the thiazole compounds in a MRSA
skin infection model, it was critical to confirm the thiazole compounds were not toxic to
human keratinocytes. Using the MTS assay with a human keratinocyte (HaCaT) cell line, it
was confirmed that thiazole compounds 1–5 were not toxic at a concentration of 10 μg/mL
(Fig 2). Interestingly, the four analogues constructed from compound 1 demonstrated an
improved toxicity profile, as they were found to be non-toxic to HaCaT cells up to a concentra-
tion of 20 μg/mL. Taken altogether, the data indicate the most potent thiazole compounds in
vitro (1–3) are not toxic to human keratinocytes at concentrations up to seven-fold higher than
the compounds’MIC values determined against MRSA.
Assessment of topical application of thiazole compounds in vivo via a
murine MRSA skin infection model
As thiazole compounds 1–5 exhibited excellent activity against MRSA in vitro and displayed
no toxicity to human keratinocytes at the compounds’MIC, we moved to confirm that these
compounds could maintain their antimicrobial activity in vivo, using an established MRSA
murine skin infection model. After the formation of an open wound (infected with MRSA) in
the dorsal region of infected mice, each group of mice was treated with a suspension of com-
pounds 1–5 (2%), mupirocin (2% suspension), or petroleum jelly (20 mg, used as a vehicle for
topical delivery of the compounds/antibiotic) twice daily for three days. The reduction in bac-
terial burden present in the wounds of infected mice was determined after cessation of treat-
ment. Reduction of bacterial burden in infected wounds is critical to promote proper wound
Table 3. Combination testing of thiazole compounds 1–3 with mupirocin against clinically-prevalent
strains of community-acquiredmethicillin-resistant Staphylococcus aureus (CA-MRSA).




1 ƩFIC, fractional inhibitory concentration index. Results for the FIC index (ƩFIC) are as follows:  0.50,
synergistic; >0.50 to 4.00, indifference; >4.00, antagonistic. ƩFIC range provided is from two independent
experiments.
doi:10.1371/journal.pone.0142321.t003
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repair and to prevent a severe inflammatory response from being triggered that may negatively
impact healing of wounded tissues [37].
As presented in Fig 3, four thiazole compounds mimic mupirocin’s ability to drastically
reduce the burden of MRSA present in skin wounds. Compounds 3–5 produce a 1.47 to 1.62
log10 reduction in MRSA CFU; this corresponds to a greater than 96% reduction in the bacte-
rial burden, as compared to mice receiving only the vehicle alone (petroleum jelly) for treat-
ment. The lead 1 exceeds the effect of mupirocin, producing a 2.27 log10 reduction in MRSA
CFU in the skin wound (relative to the 2.07 log10 reduction observed with mupirocin). The
emergence of increasing resistance to mupirocin, a drug of choice, amongst MRSA strains
makes it extremely important to find alternative options for treatment (particularly for skin
infections), such as these thiazole compounds. Interestingly, one of the most potent com-
pounds against MRSA USA300 in vitro (the biphenyl analogue 2, MIC of 2.8 μg/mL) is the
least effective compound in vivo (produces a 0.47 log10 reduction in MRSA CFU, that was
found to not be statistically significant); this provides a stark reminder that the behavior of
compounds in vitro needs to be validated with in vivo studies to confirm their viability as novel
treatment options.
Antimicrobial compounds that can be administered topically (such as thiazole compounds
1, 3, 4, and 5) for treatment of localized skin lesions have certain advantages over their systemic
counterparts. These advantages include the ability to avoid adverse systemic side effects, the
ability to localize/concentrate the drug at the target site of infection (providing increased con-
centration of the drug), lower treatment costs, and a reduced likelihood of inducing bacterial
resistance to the treatment agent [36, 38]. Overall, the results garnered from the present study
Fig 2. Toxicity analysis of thiazole compounds against human keratinocytes (HaCaT). Percent viable
mammalian cells (measured as average absorbance ratio (test agent relative to DMSO)) for cytotoxicity
analysis of thiazole compounds 1, 2, 3, 4, and 5 (tested in triplicate) at 10 and 20 μg/mL against HaCaT cells
using the MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
assay. Dimethyl sulfoxide (DMSO) was used as a negative control to determine a baseline measurement for
the cytotoxic impact of each compound. The absorbance values represent an average of a minimum of three
samples analyzed for each compound. Error bars represent standard deviation values for the absorbance
values. A one-way ANOVA, with post hoc Dunnet’s multiple comparisons test, determined statistical
difference between the values obtained for compound 1 and DMSO (denoted by the asterisk) (P < 0.05).
doi:10.1371/journal.pone.0142321.g002
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indicate the thiazole compounds (in particular the lead 1) do warrant further investigation as a
topical treatment option for MRSA-infected skin wounds.
Impact of changing vehicles in reduction of MRSA burden present in vivo
in infected skin wounds
After confirming four thiazole compounds (1, 3–5) have potential for use as novel topical anti-
microbials against MRSA, we examined if changing the vehicle used for delivery may further
enhance the reduction in bacterial burden present in infected wounds. To assess this, a 2% sus-
pension of the most potent compound (1), using Lipoderm as an alternative vehicle, was tested
using the murine MRSA skin infection model described above. Lipoderm has been used com-
mercially as a transdermal delivery vehicle to enhance permeation of active pharmaceutical
compounds through the skin [39]. It was hypothesized that switching vehicles (from petroleum
jelly) to Lipoderm would enhance penetration of the thiazole compounds into the skin wound,
thus permitting a greater reduction in the bacterial burden present. As Fig 3 demonstrates,
changing vehicles from petroleum jelly to Lipoderm does enhance the reduction in the bacterial
load in the skin wound of mice that is achieved by compound 1. A 0.4-log10 improvement in
the reduction of MRSA CFU for compound 1 is observed when Lipoderm is used. This
Fig 3. Average log10-reduction in MRSA USA300 burden in infectedmurine skin wounds. Evaluating
the effectiveness of treatment of MRSA skin lesions in mice with mupirocin (2%), thiazole compounds 1–5
(2%), and compound 1 (2%, using Lipoderm as the vehicle) twice daily for three days. The average log10-
reduction in bacterial burden (relative to the negative control group (petroleum jelly)) was calculated and
presented in the figure. Error bars represent standard deviation values. A one-way ANOVA, with post hoc
Holm-Sidak’s multiple comparisons test revealed statistical difference (denoted by asterisk) between
compounds 1, 3, 4, 5, 1 (using Lipoderm as the vehicle), and mupirocin relative to the negative control
(P < 0.05).
doi:10.1371/journal.pone.0142321.g003
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corresponds to a> 99.6% reduction in MRSA present in the skin wound after treatment. Thus
switching vehicles from petroleum jelly to Lipoderm appears to permit enhanced penetration
of the thiazole compounds into skin wounds, leading to an increased reduction in MRSA
burden.
Conclusion
In this study, we demonstrate that five novel synthetic phenylthiazole compounds exhibit
potent antimicrobial activity in vitro against clinically-relevant strains of MRSA responsible for
skin and wound infections. Additionally, compounds 1–3 exhibit a strong synergistic relation-
ship when combined with mupirocin against two highly prevalent strains of CA-MRSA. Fur-
thermore, three compounds are not toxic to human keratinocytes at a concentration seven
times higher than their MIC against MRSA. The antimicrobial activity of compounds 1, 3, 4,
and 5 is confirmed in vivo in a murine MRSA skin infection model (> 96% reduction in bacte-
rial load observed, post-treatment). Substitution of the vehicle from petroleum jelly to Lipo-
derm permits a nearly 0.4-log10 additional reduction in bacterial load achieved by compound
1, indicating this vehicle may be more suitable for enhanced penetration of the compound into
infected tissues. Collectively, the results provide valuable information to further develop these
thiazole compounds as topical antimicrobial agents for treatment of skin infections and
wounds infected by MRSA. Future work with these thiazole compounds includes constructing
additional analogues of the lead compound 1 in an effort to improve its potency against MRSA
and enhance its toxicity profile with human keratinocytes. Additionally, addressing the limited
physicochemical properties of these compounds (through structural modifications of lead
compound 1) is an important next step in order to expand the therapeutic potential of these
compounds so they can be administered orally/intravenously for treatment of invasive MRSA
infections (both complicated skin infections and systemic infections).
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